best biotech stocks asx 2021
Mar 2, 2021, Keith Speights | Learn about the risks and rapidly changing environment in this nascent industry. The company's top immunology drug, Nucala, is used in some cases of asthma and was recently approved for treating a rare blood disorder called hypereosinophilic syndrome, or HES. Since becoming CEO of Pfizer (PFE, $38.62) in 2018, Albert Bourla has been steering Pfizer away from a "patent cliff" – the loss of patent protection on older drugs. Meanwhile, Merck is expanding its breast cancer presence via a collaboration with Seattle Genetics (SGEN) on two of its assets: ladiratuzumab vedotin and Tuksya. In the U.S., the FDA oversees approvals for new drugs. Biotech stocks are once again in focus as we open another week of trading on the stock market. They require significant amounts of cash to fund operations and advance their pipeline candidates. The drug, which inhibits the action of an enzyme called PD-1, registered sales of $11 billion in 2019. This "de-risks development," getting many uses from a single compound. Second was the initial public offering of Genentech, the first true biotech stock, which proved there was money to be made int his field. However, Paul Matteis, managing director for biotechnology research at Stifel Research in Boston, noted that development of a "structurally distinct" backup compound is underway. A continued M&A focus could turn this pharmaceutical firm into one of the best biotech stocks for 2021. The COVID-19 pandemic has also created some tremendous opportunities for biotechs developing potential treatments and vaccines. The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI. The company’s pipeline includes other promising CF drugs in phase 2 testing. Alexion Pharmaceuticals (ALXN, $127.76) works on rare nerve and blood diseases such as myasthenia gravis, amyotrophic lateral sclerosis (ALS) and Guillain-Barre syndrome, where there are government incentives that ensure proven drugs can be made profitably. Jan 18, 2021 (Penny Stocks via COMTEX) -- Biotech Penny Stocks For Your January Watch List Last week was a wild one for penny stocks and blue-chip stocks alike. It’s a company that uses living organisms (for example, bacteria or enzymes) to make drugs. This use of living organisms differentiates biotechs from pharmaceutical companies, which use chemicals to develop drugs. Former President Jimmy Carter took Keytruda when it was still an experimental treatment. The small biotech’s rise from the ashes stemmed from two important developments. Real Money writer Bret Jensen reveals his top picks. Revenues are highly dependent upon Jakafi, a drug used in chemotherapy whose patents expire in late 2027. He recommends speculators put no more than 20% of assets into COVID-19 vaccine players, with BioNTech being among the most volatile. We'll start our look at emerging plays with CRISPR Therapeutics (CRSP, $82.53). Here, we'll look at 14 of the best biotech and biopharma stocks to buy for 2021. Feb 24, 2021, holds the potential to cure type 1 diabetes, Copyright, Trademark and Patent Information. Best Biotech Stocks to Buy Right Now There are plenty of opportunities in the biotechnology space, but, as with any sector, there are also plenty of risky plays. The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%. It is known for drugs like Enbrel to treat severe arthritis, Prolia to treat osteoporosis, and Neulasta, used against the side-effects of chemotherapy. Like other early-stage companies, CRISPR's stock can be highly volatile based on the results of drug trials. Moderna, Inc.(NASDAQ:MRNA): Biotech stocks should be on investors’ radars due to the COVID-19 pandemic. They see Allergan diversifying AbbVie's revenue, and say the company's "substantial cash flow" supports both the dividend and investments in new drugs. JPMorgan Chase analyst Cory Kasimov told clients the new drug is more potent than the older drug. The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment. The new compound, VX-864, targets the same disorder, but in a different way. Biopharmaceutical Merck (MRK, $81.09) sells Keytruda, the best-known immunology drug used to treat cancer. That has analysts split between buying and holding the stock, though over the past three months, Amgen has picked up more Buys (11) than Holds (10). Biochemists today work to design drugs that inhibit or activate enzymes driving biological processes. AMG 510) for the treatment of non-small cell lung cancer. With that in mind, here are four biotech giants in focus right now. There's a lot of hype around biotechnology stocks for their huge potential, but it comes with risks. Canaccord Genuity analyst Max Masucci similarly cut his price target on ILMN shares, from $350 per share to $300. The companies are prepared to deliver 200 million doses should its vaccine gain approval. But recent quarterly results have analysts nudging their price targets higher and thinking better of the biotech stock. A new Stifel research report includes the firm's biotech stock picks for 2021. "We were impressed" by how quickly the vaccine has moved toward its late-stage trial, and the results of early stage trials. "The HIV business experienced a recent flattening of US sales, but new products mean the franchise has now returned to modest growth," she writes. And it could continue to serve investors well as one of the best biotech stocks for 2021. GSK is also divesting other assets, such as a joint spin-off with Pfizer, although that has been delayed. One analyst thinks the company's foundational gene-editing tools have far more potential than many realize. It’s one of the leading vaccine candidates that use a protein subunit (a single protein molecule) to spur an immune response against the novel coronavirus. They've both already made some investors a lot of money over the last few years. Charmaine Chan, a senior analyst at Cambiar Investors in Denver, says Sanofi was ahead of today's opportunities, initiating broad partnerships with Regeneron Pharmaceuticals (REGN) and Alnylam Pharmaceuticals (ALNY) several years ago. If you're feeling bullish about the ASX in 2021 but not sure where to start, we've put together a list of ASX stocks that could be worth watching in the year ahead. Alexion has been effective in getting people with these conditions to take its drugs. B. Riley analysts note that a Phase 3 study is progressing "ahead of plan" in part thanks to a second wave of daily news cases. Credit Suisse analysts have a $725 price target on shares, saying they also believe the company could get excellent results from the drug at lower dosages. "We maintain our Strong Buy opinion as we believe that shares are still significantly undervalued because investors and analysts are generally not yet convinced that ALXN can achieve its long-term target," he says. The biotech stocks under $5 gainers and losers list are updated at the end of each market day helping penny stock traders to find the best biotech stocks … Credit Suisse analysts (Neutral) were encouraged by progress on Monjuvi after a conference call with management and a doctor from the Memorial Sloan Kettering Cancer Center. However, several analysts are rushing to upgrade their PTs: Berenberg's Zhiqiang Shu (Buy) now sees shares hitting $126, Arlinda Lee raised her price target to $115, and Merrill Lynch's Tazeen Ahmad moved his PT from $100 per share to $128. Walmsley's plan includes spinning out consumer products like Sensodyne toothpaste, Advil pain reliever and Centrum vitamins in a joint deal with Pfizer, although that has been delayed. In June, Illumina's COVIDSeq became the first COVID-19 test to win the FDA's Emergency Use Authorization. How to Track Your Tax Refund Status, Where's My Stimulus Check? >> Breaking: The Top Growth Stocks For 2021 Revealed << Best Stocks Under $1 with Potential. Novavax has also inked supply deals with Australia, Canada, the United Kingdom, and India. That makes ABBV one of the best biotech stocks to buy for investors seeking out income in 2021 and beyond. Argus Research's David Toung notes that Merck has two COVID-19 vaccine candidates ready for clinical trial, along with an antiviral, developed in collaboration with Ridgeback Biotherapeutics, that can be taken as a pill. But like with most smaller biotechs, handle BNTX with care. Within 18 months of getting approval for Ultomiris – a treatment for a blood disease called paroxysmal nocturnal hemoglobinuria, which tears red blood cells apart – 70% of sufferers in the U.S. were using it. In addition, a biotech with more experimental drugs in its pipeline (the term used to refer to all a company’s drugs that are in development) will tend to have less risk than a biotech with only one or a very few drug candidates. CRISPR currently has a treatment for sickle cell disease, as well as three anti-cancer compounds, in early-stage studies. Investors prefer drugs that treat diseases in a new way, "rather than a portfolio of drugs that uses more 'established' technology with smaller peak sales potential.". The acquisition is adding to both top- and bottom-line growth. Vertex (NASDAQ:VRTX) enjoys a virtual monopoly in treating the underlying cause of cystic fibrosis (CF), a rare genetic disease that results in the excessive buildup of mucus in the lungs and digestive system. StatNews, which covers the industry, cites four events within two months as vital: Modern biotech begins with DNA, first discovered in the 1950s, and the chemical interactions it induces to create life. Combined with Celgene's Revlimid, it allows for control of some forms of B-cell lymphoma. It’s also evaluating AXS-05 in a phase 2 study for smoking cessation. Find the latest information in the newsfeed at the end of this article. Past its COVID-19 vaccine, Cambiar Investors' Chan believes BNTX can "be a one-stop shop" for mRNA, cell and gene therapies, complete with diagnostic and manufacturing. Mar 4, 2021, Cory Renauer | Its collaboration with Pfizer has so far yielded success, and the drug's early data from Phase 3 trials has many analysts optimistic about an approval. CFRA's Kevin Huang maintains a Strong Buy rating on the biotech stock. But then, biotech and biopharmaceutical companies been all the rage for much of the past few decades. A few of them have also made significant progress in developing a vaccine or a treatment for the deadly infection. In addition, 2021 is setting up to be a catalyst-rich year for the company with data readouts across its immuno-oncology pipeline and the initiation of a Phase I/II trial with ViaCyte for the treatment of diabetes Type I.". Biotech stocks have been all the rage in 2020 as a number of companies have aspired to correct the COVID-19 pandemic. ), a big beat on Rinvoq revenues and a 10% dividend increase, among others. If an Emergency Use Authorization is granted, BioNTech and Pfizer would share a $1.95 billion prize for 100 million doses, which could be expanded to 500 million. There are four major steps for biotechs in developing new drugs: Clinical testing typically involves three phases: A drug candidate must successfully make it through each phase to advance to the next. Travel stocks are expected to enjoy a massive tailwind as more Americans are immunized against COVID ... and Wall Street knows it. That purchase gives Illumina even more long-term potential – but it has clouded the waters in the near-term, giving analysts some pause. Pfizer recently released early data, saying that its "vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis.". However, William Blair analyst David Tuong is more optimistic. In addition, Vertex’s early-stage programs could be game changers. He continues to maintain a Buy rating on the stock with a price target of $309, representing 37% upside from here. Given its vaccine work, it's no surprise GSK is working on a COVID-19 vaccine with Sanofi, which Walmsley recently said will be sold at no profit. The later the phase, the less risk there usually is. Mar 2, 2021, Motley Fool Transcribers | In this article we will list the 10 best small-cap biotech stocks under $10 in 2021. City Chic Collective (ASX CCX) is an Omnichannel Retailer expanding into the US and UK March 3, 2021; 5 Best High Growth Stocks To Buy For 2021 [ASX Research] March 3, 2021; 5 Best Small Cap Stocks To Buy For 2021 [ASX Research] March 3, 2021; Origin Energy (ASX ORG) is a High Yield Dividend Play with Growth Potential February 24, 2021 Mar 5, 2021, Eric Volkman | They also don't see LY-CoV555, a similar compound from Eli Lilly (LLY), as a threat. Its newest CF drug, Trikafta/Kaftrio, could expand the addressable patient population by more than 50% by targeting a genetic mutation estimated to occur in 90% of CF patients. This arm does about $6.5 billion in annual sales. Another important thing to watch with biotechs is their financial positions. NVAX stock has exploded in 2020 thanks to its work with COVID-19, with shares – which started the year around $4 – up a whopping 2,300-plus percent year-to-date. Two say it's a Strong Buy, two more say it's a Buy, and one disagrees with a Strong Sell recommendation. Exelixis (NASDAQ:EXEL) has developed four drugs that are currently on the market. These deeply discounted stocks are perfect for patient investors. The company stopped development of lung drug VX-814, after a Phase 2 study showed it caused unusually high levels of liver enzymes. The trend started within just a couple of months 40 years ago this fall. This golden age is also presenting tremendous opportunities for investors. Which one will be the better choice this year? AXSM earnings call for the period ending December 31, 2020. The best biotech ETFs for Q2 2021 are ARKG, IDNA, and XBI. Indeed, AbbVie is one of a handful of dividend growth stocks that delivered double-digit payout increases this year, effectively ensuring another year of membership in the Dividend Aristocrats: stocks that have raised their payouts annually for at least 25 consecutive years. Scientists with promising research also have launched companies sometimes worth billions of dollars before they even have a treatment on the market. CRISPR itself was co-founded by Charpentier, Shaun Foy and Rodger Novak, who is president and chairman. There's a pretty good chance the answer is "yes.". Small Caps and affiliated companies accept no responsibility for any claim, loss or … The failure of VX-814 increased concerns of some analysts over the company's pipeline of new drugs. If approved, AXS-05 could generate peak annual sales of at least $1 billion, making it a blockbuster drug, with one analyst projecting peak sales of $2.6 billion. Hudson is selling passive investments and becoming an aggressive acquirer of other drug companies. He writes that "We are encouraged by REGN-COV2 data and see a strong need in the seronegative patient population. Its latest approved drug is Monjuvi, a lymphoma treatment. We also believe that the drug can be used at a lower dose, extending dosing capacity.". Before the pandemic began, BionTech was considered a niche player, focused on cancer treatments. The company expects to file for U.S. regulatory approval for the drug in treating depression in early 2021. In addition to having targeted therapies and immunological drugs against cancer, Incyte's pipeline includes drugs for autoimmune diseases like dermatitis. We cover how to find the best stocks in the biotech sector. Its acquisition of Allergan, completed in 2020, also gives AbbVie new markets in plastic surgery, neurology, eye care and women's health. One risk is that BNTX, which is already one of the best biotech stocks of 2020 thanks to a tripling in its shares, has "outkicked its coverage." He adds that the company "Could be a potential takeout candidate" given the optionality of the CRISPR-Cas9 platform and potential cost-effectiveness. In October, Alexion had seven more treatments for rare diseases in clinical trial and planned to begin trials on five more. These stocks made investors a lot of money in 2020. "Sanofi has bigger ambitions" to position it "as a backbone agent for future novel combinations. Keith Speights and Brian Orelli, PhD | But Axsome, Exelixis, Novavax, and Vertex could also be successful with their clinical studies and win approvals to launch their promising drugs. The shares recently fell 10% after a patient died during the Phase 1 study of its CTX110, a treatment for B-cell lymphoma also targeted by Incyte's Monjuvi. The drug, which inhibits a protein found in the C5 gene, is also under consideration as a treatment for myasthenia gravis, a neuromuscular disease, and neuromyelitis optica spectrum disorder, which inflames the optic nerve. As mentioned earlier, Germany-based BioNTech (BNTX, $106.00) is one of several biotech stocks trying to bring a COVID-19 vaccine to the market. While clearly REGN-CoV2 has boosted the stock, the company itself has enjoyed double-digit revenue growth on average over the past few years. Analysts such as UBS's Laura Sutcliffe are focused on Libtayo, which uses the body's own immune system to treat cancer. Specifically, Pfizer has had to deal with patent expirations on blockbuster drugs such as Viagra and Lipitor. Its ResVax vaccine failed two trials. We'll divide these opportunities into three buckets: 1.) Net income is much more erratic but in general is trending in the right direction (higher). Mar 5, 2021, Keith Speights | Nonetheless, 17 of the 22 analysts covering the stock rate it a Buy or Strong Buy; the remaining five say you should still hold on to shares if you own them. It’s partnering with CRISPR Therapeutics (NASDAQ:CRSP) to test gene-editing therapies (treatments that involve changing DNA sequences) targeting the rare blood diseases beta-thalassemia and sickle cell disease. Here’s what you need to know to invest in the best biotech stocks on the market. In addition, the biotech plans to file for approval of experimental migraine drug AXS-07 in the first quarter of 2021 and has two other drug candidates in earlier-stage clinical trials. "BNTX expertly executed on both development and partnership fronts, showcasing their mRNA expertise," she says. The best biotech companies to invest in tend to have strong growth. But that was true for ResVax as well. If the new compound works, Vertex is very undervalued. Mar 4, 2021, Sean Williams | For this reason, it could be one of the biotech penny stocks to watch heading into 2021. The company said it plans to launch 10 new drugs by 2023, and buy back $3 billion in stock. Regeneron Pharmaceuticals (REGN, $566.43), responsible for drugs such as macular degeneration Eylea and arthritis treatment Kevzara, has made headlines in 2020 for the monoclonal antibody cocktail REGN-CoV2, which was used to treat President Donald Trump's COVID-19 infection. Meanwhile, the Phase 3 study of omecamtiv mecarbil, Amgen's new drug to treat heart failure, failed to meet its secondary endpoint of reducing deaths from subsequent heart failure, causing some analysts to downgrade the stock. TheMaven (OTC: … He has a price target of $55 on Pfizer, based in part on the COVID-19 vaccine. Analysts project that, if approved, NanoFlu could generate peak annual sales of as much as $1.7 billion. As "physician offices reopen, elective surgeries resume, and pet owners return to veterinary offices," he expects results to steadily improve. Bourla is trying to unlock value in several ways. But a few pros think this time really might be different. Some analysts remain in the Hold camp, worried that Pfizer is already pricing in a good-case vaccine scenario. Search for the best biotech penny stocks under $5 that are trading on NASDAQ and NYSE. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Cambiar Investors' Chan says the key to success with Jakafi is to find new diseases for it to treat and new ways to administer it. 3 Top Biotech Stocks for 2021 MRNA – While many growth stocks are selling-off on the vaccine news, one growth sector that should keep outperforming in 2021 is biotech stocks. Shares in this biotech stock are currently recovering from a nasty 25% drop in the wake of a significant setback. Canaccord Genuity analyst John Newman has a Buy rating and $700 price target on shares. "We do not see this as a zero-sum game," the analysts add. Its biggest winner by far is Cabometyx. Steve Azoury, owner of Azoury Financial in Troy, Michigan, says the company's future is closely tied to the vaccine. UBS's Sutcliffe also sees GSK as a Buy. The company now plans to pursue Food and Drug Administration (FDA) approval of the vaccine. Big Pharma stocks that are undergoing (or have undergone) shifts to become more biotech-minded; 2.) While Amgen called the results positive, some analysts questioned that conclusion. Emerging markets stocks are in the same position as domestic equities right now: There's still plenty more recovery upside to go. The company reported overwhelmingly positive results from a late-stage study of experimental flu vaccine NanoFlu. Here are 2 biotech stocks on the ASX that could potentially be the next CSL. Sustainable stocks are going gangbusters. The drug is approved for treating renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC), the most common types of kidney cancer and liver cancer, respectively. Jakafi can be injected for blood diseases but taken orally to treat skin diseases. Novavax's vaccine candidate, called NVX-CoV2373, is boosted with an adjuvant called Matrix-M, which makes it possible to vaccinate more people with less of the drug. They also view Pfizer and BioNTech's success as favorable to the likelihood of technical success for Novavax's program, "which is contrary to NVAX's equity weakness (of late) and in part also driven by investor confusion" regarding the company's financials. The move illustrates the big risks in biotech, namely the unpredictability of clinical trials. The best biotech stocks to buy right now boast strong pipelines, and some already have winning drugs on the market. But also, Pfizer will get $12 billion in the Viatris spin-off, he writes, and will retain such drugs as Ibrance, Eliquis, Vyndaqel, Xtandi and Xeljanz, as well as its own research in oncology, immunology, rare diseases and vaccines.